HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Jan. 24, 2018 (HealthDay News) -- Next-generation sequencing may be useful for identifying causative organisms in culture-negative periprosthetic joint infection, according to a study published online Jan. 17 in The Journal of Bone & Joint Surgery.
Majd Tarabichi, M.D., from The Rothman Institute at Thomas Jefferson University in Philadelphia, and colleagues collected samples from 65 revision arthroplasties and 17 primary arthroplasties in a prospective study. At the time of surgery, synovial fluid, deep tissue, and swabs were obtained, and they were shipped to the laboratory for next-generation sequencing.
The researchers found that the cases were considered to be infected in 28 revisions; cultures and next-generation sequencing were positive in 17 and 25 cases (60.7 and 89.3 percent, respectively); in 15 cases there was concordance between culture and next-generation sequencing. Next-generation sequencing was able to identify an organism in nine of the 11 cases of culture-negative periprosthetic joint infection (81.8 percent). Microbes were identified by next-generation sequencing in nine of 36 aseptic revisions of negative cultures (25 percent) and in six of 17 primary total joint arthroplasties (35.3 percent). In most positive samples, next-generation sequencing detected several organisms; however, one or two organisms were dominant in the majority of patients who were infected.
"Further study is required to determine the clinical implications of isolated organisms in samples from patients who are not thought to be infected," the authors write.
One author disclosed financial ties to MicroGen Dx, the laboratories that were used for next-generation sequencing of the samples, as well as to the medical products industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 28, 2022